The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma

This is the authors' abstract. We don't add key points for this paper.

// Ying Guan 1, 2, * , Anchuan Li 3, * , Weiwei Xiao 1, * , Shuai Liu 4 , Binbin Chen 1 , Taixiang Lu 1 , Chong Zhao 1 , Fei Han 1 1 Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China 2 Department of Radiation Oncology, Affiliated Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China 3 Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350009, P. R. China 4 Department of Radiotherapy Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, P. R. China * These authors have contributed equally to this work Correspondence to: Chong Zhao, e-mail: gzzhaochong@hotmail.com Fei Han, e-mail: hanfeisysucc@163.com Keywords: Endostar, nasopharyngeal carcinoma, recurrence, chemotherapy, intensity-modulated radiotherapy Received: March 13, 2015 Accepted: September 04, 2015 Published: September 15, 2015 ABSTRACT Purpose: To evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC). Materials and Methods: Between March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m 2 ) for 14 days (Days 1–14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed. Results: Until January 2014, the median follow-up time was 13 months (range, 4–41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3–5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22). Conclusions: Endostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.